公开(公告)号：US20180195133A1

公开(公告)日：2018-07-12

申请号：US15836729

申请日：2017-12-08

Applicant: Genentech, Inc.

Inventor： Mahrukh HUSENI

IPC: C12Q1/6886 ,  C07K16/28 ,  G01N33/574

Abstract: The present disclosure provides methods for predicting responsiveness of a subject having cancer to an OX40 agonist treatment by measuring the expression level of one or more biomarkers. Also provided are methods for monitoring pharmacodynamic activity of or responsiveness to an OX40 agonist treatment by measuring the expression level of one or more biomarkers. Further provided are methods related thereto for treating or delaying progression of cancer in a subject by administering an effective amount of an OX40 agonist to a subject. Specific biomarkers for all such methods are described herein.

公开(公告)号：US20170000885A1

公开(公告)日：2017-01-05

申请号：US15176106

申请日：2016-06-07

Applicant: Genentech, Inc.

Inventor： Ina P. RHEE ,  Jeong KIM ,  Mahrukh HUSENI ,  Eric STEFANICH ,  Sid SUKUMARAN ,  Chi-Chung LI

IPC: A61K39/395 ,  A61K9/00

CPC classification number: A61K39/3955 ,  A61K9/0019 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/545 ,  C07K16/2827 ,  C07K16/2878 ,  C07K2317/24 ,  C07K2317/75 ,  C07K2317/76

Abstract: The invention provides methods of treating or delaying progression of cancer in an individual comprising administering to the individual an anti-human OX40 agonist antibody and an anti-PDL1 antibody. In some embodiments, the anti-human OX40 agonist antibody is administered in a dose selected from about 0.8 mg, about 3.2 mg, about 12 mg, about 40 mg, about 80 mg, about 130 mg, about 160 mg, about 300 mg, about 320 mg, about 400 mg, about 600 mg, and about 1200 mg, and the anti-PDL1 antibody is administered at a dose of about 800 mg or about 1200 mg.

Abstract translation: 本发明提供治疗或延缓个体中癌症进展的方法，包括向个体施用抗人OX40激动剂抗体和抗PDL1抗体。 在一些实施方案中，抗人OX40激动剂抗体以约0.8mg，约3.2mg，约12mg，约40mg，约80mg，约130mg，约160mg，约300mg， 约320mg，约400mg，约600mg和约1200mg，并且抗PDL1抗体以约800mg或约1200mg的剂量施用。